Previous Article | Next Article ![]()
J Virol, January 1998, p. 460-466, Vol. 72, No. 1
Division of Biology
156-291 and
Howard Hughes Medical
Institute,2 California Institute of
Technology, Pasadena, California 91125
Received 5 August 1997/Accepted 6 October 1997
Both human and murine cytomegaloviruses (HCMV and MCMV)
down-regulate expression of conventional class I major
histocompatibility complex (MHC) molecules at the surfaces of infected
cells. This allows the infected cells to evade recognition by cytotoxic
T cells but leaves them susceptible to natural killer cells, which lyse
cells that lack class I molecules. Both HCMV and MCMV encode class I
MHC heavy-chain homologs that may function in immune response evasion.
We previously showed that a soluble form of the HCMV class I homolog
(UL18) expressed in Chinese hamster ovary cells binds the
class I MHC light-chain Cytomegaloviruses (CMVs) are
ubiquitous, host-specific pathogens that are capable of
establishing lifelong infections in immunocompetent hosts. Although
acute infection will elicit an immune response, this response usually
fails to completely resolve the infection. Instead, the virus persists
in the host, often in a state of latency, and recurrent infections may
be observed if the animal becomes immunocompromised (5). In
order to maintain this degree of persistence, especially in the face of
a fully primed immune system, CMVs have developed various means of
modulating the host immune system. One strategy used by both human and
murine CMVs (HCMV and MCMV) is the down-regulation of host class I
major histocompatibility complex (MHC) molecules (6). Class
I MHC molecules are polymorphic glycoproteins composed of a
membrane-bound heavy chain associated with a nonpolymorphic light
chain, Although interference with class I-mediated antigen presentation or
class I expression may enable infected cells to evade virus-specific T
cells, it may also render these cells susceptible to detection and
lysis by NK cells. NK cells express both activating and inhibitory
surface receptors (31). The activating receptors are
predominantly triggered by non-MHC molecules, while the inhibitory receptors recognize class I MHC molecules (31). Stimulation of activating receptors leads to target cell lysis unless the NK cell
inhibitory receptors are able to engage an adequate level of self class
I molecules on the target cell (27). Therefore, those cells
that have down-regulated their class I molecules to a level sufficient
to avoid T cells can be recognized and eliminated by NK cells.
As a possible means of undermining the host NK cell response, both HCMV
and MCMV encode MHC class I homologs (2, 14, 39). It has
been hypothesized that the role of these homologs in a virus-infected
cell is to engage NK cell inhibitory receptors, thereby preventing the
lysis that would normally occur due to down-regulation of class I
molecules (11, 14, 40). In this way virus-infected cells are
less susceptible to lysis by both cytotoxic T lymphocytes and NK cells.
The HCMV-encoded homolog, UL18, is a 348-residue type I
transmembrane glycoprotein whose extracellular region shares ~25%
amino acid sequence identity with the extracellular regions of human
class I molecules (2) (Fig.
1A). Like class I MHC molecules,
UL18 associates with
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Characterization of a Murine Cytomegalovirus Class
I Major Histocompatibility Complex (MHC) Homolog: Comparison to
MHC Molecules and to the Human Cytomegalovirus MHC
Homolog
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
2-microglobulin and a mixture of endogenous
peptides (M. L. Fahnestock, J. L. Johnson, R. M. R. Feldman, J. M. Neveu, W. S. Lane, and P. J. Bjorkman,
Immunity 3:583-590, 1995). Consistent with this observation, sequence
comparisons suggest that UL18 contains the
well-characterized groove that serves as the binding site in MHC
molecules for peptides derived from endogenous and foreign proteins. By
contrast, the MCMV homolog (m144) contains a substantial deletion
within the counterpart of its
2 domain and might not be expected to
contain a groove capable of binding peptides. We have now expressed a
soluble version of m144 and verified that it forms a heavy
chain-
2-microglobulin complex. By contrast to UL18 and
classical class I MHC molecules, m144 does not associate with
endogenous peptides yet is thermally stable. These results suggest that
UL18 and m144 differ structurally and might therefore serve
different functions for their respective viruses.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
2-microglobulin (
2m). Class I molecules present peptides
derived from the degradation of cytoplasmic proteins to cytotoxic T
cells, thus enabling them to survey the status of the interior of the
cell (49). In an uninfected cell, MHC molecules bind
peptides derived from self proteins to which T cells are tolerant.
However, in an infected cell, some MHC molecules are occupied by
peptides derived from viral proteins, to which T cells react by killing
the cell. By down-regulating MHC class I molecules, viruses are able to
elude viral-antigen-specific cytotoxic T cells.
2m (6). We previously
showed that a soluble form of UL18 expressed in Chinese
hamster ovary (CHO) cells binds a mixture of endogenous peptides with
characteristics similar to those of peptides eluted from class I
molecules, that is, "anchor" residues, and a predominance of short
peptides derived from cytoplasmic proteins (11). The MCMV-encoded MHC homolog, m144, is a 383-residue type I transmembrane glycoprotein whose extracellular region shares ~25% amino acid sequence identity with the corresponding part of murine class I MHC
extracellular regions (14, 39) (Fig. 1A). The two viral homologs are not closely related to each other, sharing only 18% sequence identity, thus requiring that m144 be separately
characterized.

View larger version (37K):
[in a new window]

View larger version (33K):
[in a new window]
FIG. 1.
Comparison of MCMV and HCMV class I homologs with class
I MHC molecules. (A) Sequence alignment of the mature extracellular
regions of m144 with a murine class I molecule (muMHC) and of
UL18 with a human class I MHC molecule (huMHC) (based on
data from Fig. 1 in reference 14). Numbering is with
reference to class I MHC molecules. Crystallographically determined
secondary-structural elements in class I MHC molecules (3)
are shown above the sequences as arrows for
strands (strands 1 through 8 within the
1 and
2 domains are labeled
1 to
8, and strands 1 through 7 within the
3 domain are labeled A to
G) and spirals for
-helical regions. Positions of conserved
tyrosines in the pocket that accommodates peptide N termini (pocket A
in class I MHC molecules [45, 47]) are marked with an
asterisk, and potential N-linked glycosylation sites are underlined.
(B) Locations of UL18 and m144 sequence insertions and
deletions on the class I MHC structure. Ribbon diagrams of the
carbon-
backbone of the
1 and
2 domains of HLA-A2 (4,
45) are shown with the locations of UL18 or m144
insertions indicated by asterisks; class I regions that are deleted in
UL18 or m144 are indicated by dashed lines. Conserved
tyrosines shared between UL18 and class I molecules are
highlighted in the left panel. This figure was generated by using
Molscript (28) and Raster-3D (34).
In this paper we describe the expression and biochemical
characterization of a soluble version of m144. We find that, like UL18 and class I MHC molecules, m144 binds
2m, but
unlike these other proteins, it does not associate with endogenous
peptides. We further demonstrate that m144 is thermally stable in the
absence of bound peptide, unlike both class I MHC molecules (13,
33, 46, 50) and UL18. Taken together with a sequence
comparison of m144 with class I MHC molecules, these results suggest
that the m144 counterpart of the MHC peptide-binding site differs from those of both class I molecules and UL18 (Fig. 1B).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Construction of the m144 expression plasmid. Molecular cloning manipulations were performed by standard protocols (43). PCR was used to insert a 5' XhoI site, a 3' NotI site, and a stop codon after the codon corresponding to amino acid 241 of the m144 gene (the HindIII fragment I of MCMV strain K181 was kindly provided by Helen Farrell, University of Western Australia, Nedlands). Our numbering scheme starts with the first residue of the mature protein, which is designated residue 1, and all other residues are numbered sequentially (see "N-terminal sequencing of purified m144" below). The PCR product was cloned into pBSIISK+ (Stratagene), and the sequence was verified. The modified m144 gene was then removed from pBSIISK+ by using XhoI and NotI and was subcloned into the unique XhoI and NotI sites of the expression vector PBJ5-GS (16). PBJ5-GS carries the glutamine synthetase gene as a selectable marker and as a means of gene amplification in the presence of the drug methionine sulfoximine, a system developed by Celltech (1).
Construction of the murine
2m (b allele) expression
plasmid.
An expression plasmid containing the a allele of murine
2m (m
2ma) was previously constructed in our
laboratory (12). This allele of
2m, however, is not
recognized by the anti-m
2m monoclonal antibody (MAb) S19.8
(48). Originally anticipating that m144-m
2m heterodimers
could be purified by S19.8 immunoaffinity chromatography, we used
site-directed mutagenesis to change m
2ma to
m
2mb. This m
2ma gene was excised by using
XbaI and XhoI and was subcloned into the same
sites in pBSKS+ (Stratagene). The a and b alleles of m
2m differ by
only 1 nucleotide, which changes residue 85 from Asp to Ala
(15). The single nucleotide was altered by
oligonucleotide-directed in vitro mutagenesis (29), and the
sequence was verified. The modified m
2m gene was then removed from
pBSKS+ by using XbaI and XhoI and was
subcloned into the unique XbaI and XhoI sites of
the expression vector PBJ1 (32). Unfortunately, the
m
2mb epitope recognized by the antibody S19.8 is
inaccessible when the protein is complexed to the m144 heavy chain, as
verified in immunoprecipitation experiments (data not shown).
Cell culture and transfection.
The m144 expression plasmid
was cotransfected with either a human
2m (h
2m) (13)
expression vector or the previously described m
2m expression vector
into CHO cells by a Lipofectin procedure (GIBCO BRL). Cells resistant
to 100 µM methionine sulfoximine were selected according to the
protocol established by Celltech, modification of which has been
previously described (16). Transfected CHO cells were
maintained in glutamine-free
minimal essential medium (Irvine
Scientific) supplemented with 5% dialyzed fetal bovine serum (GIBCO
BRL), 100 µM methionine sulfoximine (Sigma), penicillin (100 U/ml),
and streptomycin (100 µg/ml). Cells secreting m144-
2m heterodimers
were identified by immunoprecipitation of supernatants of cells
metabolically labeled with [35S]methionine and
[35S]cysteine (see below) by using either an antibody
against h
2m (BBM.1) (36) or anti-m144 antiserum. Clones
were considered positive if immunoprecipitation yielded a heavy chain
of 44 kDa and a light chain of 12 kDa. The heavy chain was verified to
be m144 by N-terminal sequencing (see below).
35S metabolic labeling. m144-transfected CHO cell lines derived from colonies were expanded into 12-well trays, grown to confluence, and incubated for 5 h in 1.0 ml of methionine- and cysteine-free medium (GIBCO BRL) plus 1% dialyzed fetal bovine serum including 5 µCi of a [35S]methionine and [35S]cysteine (ICN) mixture. Supernatants were clarified by a 5-min spin in a microcentrifuge, and either BBM.1 or anti-m144 antiserum (see below) was added. Immunoprecipitations were carried out by standard methods (21) with protein G-bearing Sepharose beads (Pharmacia). Samples were boiled in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) running buffer and loaded onto 15% polyacrylamide gels, which were fixed, dried, and exposed to a PhosphorImager screen (Molecular Dynamics). The image was then developed with a Molecular Dynamics 425E phosphorimage scanner.
Protein purification.
m144-h
2m- and m144-m
2m-secreting
CHO cell lines were grown to confluence in 50 10-cm plates.
Supernatants were collected every 3 days for 1 month. Soluble
m144-h
2m heterodimers were purified from the supernatants on a BBM.1
immunoaffinity column. This affinity column was prepared by coupling 70 mg of the BBM.1 MAb to cyanogen bromide-treated Sepharose 4B
(Pharmacia) at approximately 10 mg of antibody/ml of resin according to
the protocol of the manufacturer. Supernatants were passed over the
affinity column, which was then washed with 50 column volumes of a
solution consisting of 50 mM Tris (pH 7.4), 0.1% NaN3, and
1 mM EDTA. Free
2m and m144-h
2m heterodimers were eluted from the
BBM.1 column with 50 mM diethylamine (pH 11.5) into tubes containing
1.0 M Tris (pH 7.4). Free h
2m was separated from m144-h
2m
heterodimers by using a Superdex 200 HR 10/30 fast protein liquid
chromatography (FPLC) filtration column. Approximately 3 mg of
m144-h
2m heterodimers was recovered per liter of transfected cell
supernatants. Soluble m144-m
2m heterodimers were purified from the
supernatants on a 15C6 immunoaffinity column made by coupling an
anti-m144 MAb (see below) to Sepharose beads as described above.
Supernatants from m144-m
2m-secreting CHO cell lines were passed over
the column, the column was washed, and the protein was eluted as
described above. A second protein migrating with an apparent molecular
mass of 93 kDa coeluted with the m144-m
2m heterodimer and was
separated by using a Superdex 200 HR 10/30 FPLC filtration column.
Approximately 1 mg of m144-m
2m heterodimer was recovered per liter
of transfected cell supernatants.
N-terminal sequencing of purified m144.
N-terminal
sequencing was performed on 2.3 µg of purified soluble m144-h
2m or
m144-m
2m in a phosphate buffer dried onto a poly(vinylidene
difluoride) membrane and inserted into an Applied Biosystems model 476A
sequencer reaction cartridge. Two sequences were isolated from the
m144-h
2m sample: the sequence IQRTPKIQVYSRHPAEN, corresponding
to the first 17 residues of mature h
2m (26), and the
sequence HGTEDSSESGLRYAYT, corresponding to the first 17 residues of
the mature m144 heavy chain (reference 14 and data
not shown). Two sequences were also isolated from the m144-m
2m sample: the sequence IQKTPQIQVYSRHPPEN, corresponding to the first 17 residues of mature m
2m (17), and the residues given
above for the m144 heavy chain.
Acid elution and characterization of peptides.
Purified
secreted UL18, m144-h
2m, m144-m
2m, FcRn (a class I
MHC homolog that functions as a receptor for the Fc portions of
immunoglobulin G [16]), and H2-Kd-h
2m
(a murine class I MHC heavy chain complexed with h
2m
[13]) proteins were analyzed for the presence of bound
peptides. All these proteins were produced in CHO cells as described
above for m144. In these experiments, FcRn served as the negative
control, since it had previously been established by biochemical and
crystallographic methods that it does not associate with endogenous
peptides (7, 37), while UL18 and Kd
served as positive controls, since endogenous peptides had previously been characterized from samples of these proteins (11, 37). Acid elutions and sequencing were performed by established methods (24, 42, 51). Briefly, 0.25 mg of protein was concentrated to 100 µl in a Centricon 3 (molecular weight cutoff, 3,000)
ultrafiltration device (Amicon; Beverly, Mass.). After dilution with
1.0 ml of 50 mM ammonium acetate (pH 7.5), the proteins were again
concentrated to 100 µl, and this procedure was repeated. The washed
protein was then treated with 1.0 ml of 12% acetic acid, heated to
70°C for 5 min, and subsequently concentrated again to 100 µl in
the ultrafiltration unit, with the filtrate containing any eluted material. This elution step was then repeated. The acid eluates were
lyophilized and analyzed by automated Edman degradation with an Applied
Biosystems model 476A protein sequencer (see Table 1). Eluates
were also analyzed with a Perkin-Elmer/Applied Biosystems Inc. model
172A microbore high-pressure liquid chromatograph (HPLC) and a Reliasil
C18 (Reliasil Column Engineering) column. Material was eluted by using a 3-ml gradient from 0.05% trifluoroacetic acid in
water to 0.05% trifluoroacetic acid in 40% acetonitrile. Absorbance was monitored at 200 nm. The fractions containing peaks were
analyzed by matrix-assisted, laser desorption, time-of-flight mass
spectrometry with a PerSeptive Biosystems (Farmingham, Mass.) ELITE
mass spectrometer.
CD analyses.
An Aviv 62A DS spectropolarimeter equipped with
a thermoelectric cell holder was used for circular dichroism (CD)
measurements. Wavelength scans and thermal denaturation curves were
obtained from samples containing 10 µM protein in 5 mM phosphate at
pH 7 by using a 0.1-mm path length cell for wavelength scans and a 1-mm
path length cell for thermal denaturation measurements. The
heat-induced unfolding of UL18, m144-h
2m, m144-m
2m,
and H2-Kd-h
2m was monitored by recording the CD signal
at 223 nm while the sample temperature was raised from 25 to 75°C at
a rate of approximately 0.7°C/min. The transition midpoint
(Tm) for each curve was determined by taking the
maximum of a plot of d
/dT versus T (where
is ellipticity) after averaging the data with a moving window of 5 points.
Production of MAbs and polyclonal antiserum.
Three MAbs were
generated for the studies presented here, two specific for m144-
2m
and one specific for the UL18 heavy chain. Of those that
recognize m144-
2m, 15C6 was raised against a gel slice of the m144
heavy chain and 19G4 was raised against the m144-h
2m heterodimer.
Female BALB/c mice (5 weeks old) were primed and twice boosted at
2-week intervals by intraperitoneal injection of either a 5- by 10- by
1.5-mm homogenized gel slice containing m144 or 100 µg of purified
soluble m144-h
2m. Serum was screened 1 week after each injection by
enzyme-linked immunosorbent assay (ELISA). Three days preceding the
fusion, one mouse was boosted with a gel slice or 100 µg of purified
m144 in phosphate-buffered saline. Splenocytes from the boosted mouse
were fused with HL-1 murine myeloma cells, and media from the hybridoma
cultures were tested for antibodies against the m144 heavy chain by
ELISA. After subcloning of positive clones at clonal density, ascites
tumors were produced in pristane-primed BALB/c mice. In addition, a
rabbit antiserum recognizing m144 was raised against a gel slice of the m144 heavy chain (Antibodies Incorporated, Davis, Calif.). Both MAbs
and the antiserum are effective reagents in an ELISA for detection of
m144-
2m, immunoprecipitation of soluble m144-
2m heterodimers, and
Western blotting. The UL18-specific MAb, 10C7, was prepared
similarly to m144-specific MAbs; however, the mice used were female
OLA × BL6 h
2m transgenic mice (a kind gift of H. Ploegh,
Massachusetts Institute of Technology) injected with enzymatically
deglycosylated UL18-h
2m heterodimers. Several
previous attempts to isolate an antibody against the UL18
heavy chain in nontransgenic mice failed, presumably because
UL18 is heavily glycosylated (13 potential N-linked
glycosylation sites [2]), so that an antibody
recognizing a protein epitope within UL18 rather than
2m
was difficult to isolate. Indeed, all hybridomas screened from
nontransgenic mice produced antibodies that recognized h
2m instead
of the heavy chain. By using h
2m transgenic mice, many potential
MAbs against the heavy chain were generated. A rabbit antiserum
recognizing UL18 was raised against a gel slice of the
UL18 heavy chain (HRP Inc., Denver, Pa.). Both the MAb and
the antiserum are effective reagents in an ELISA for detection of
UL18-h
2m, immunoprecipitation of soluble
UL18-h
2m heterodimers, and Western blotting.
Preparation of peptide-filled UL18 and
H-2Kd.
UL18 was purified from the
supernatants of UL18-h
2m-secreting cells (11)
grown in a hollow-fiber bioreactor device (Cell Pharm I; Unisyn
Fibertec, San Diego, Calif.). Using this system, only 35 to 40% of the
molecules appear to contain endogenous peptides, compared to
UL18 produced from transfected cells grown on plates, which
appears to be fully occupied (11). As previously described (11), we calculated the percent of UL18 occupied
with peptide by comparing the amount of peptide material eluted from
H-2Kd with the amount eluted from UL18 when the
number of picomoles of starting protein is the same. The peptide
ALPHAILRL, previously identified as a major component of
UL18 acid eluates (11), was synthesized with an
Applied Biosystems 433A peptide synthesizer. The peptide was incubated
with UL18 at a 20:1 molar ratio for 12 h at room
temperature. Unbound peptides were separated from UL18 by
passing the mixture over a Superdex 200 HR 10/30 FPLC size exclusion
column. H-2Kd was purified from supernatants of
Kd-h
2m-secreting cells grown on 10-cm plates. Previous
characterization of soluble Kd established that ~70% of
the protein is empty and ~30% is occupied by endogenous peptide
(13). The peptide SYIPSAEKI, previously identified as a
Kd-binding peptide (12, 41), was synthesized and
incubated with partially empty Kd, and unbound peptide was
separated from Kd-peptide complexes as described above for
preparation of peptide-filled UL18.
| |
RESULTS |
|---|
|
|
|---|
Soluble m144 associates with h
2m and m
2m.
To investigate
whether m144 binds
2m and serves as a peptide receptor, we expressed
a soluble version of m144 in CHO cells together with h
2m or m
2m.
The soluble version of m144 was constructed by truncating the gene
prior to the predicted transmembrane region (following residue 241 of
the mature protein). Initial experiments were performed with the h
2m
gene in order to facilitate detection of the protein product with the
antibody BBM.1 (36), which binds to h
2m but not to
m
2m. Transfected cells were screened by immunoprecipitating metabolically labeled supernatants with BBM.1. SDS-PAGE analysis of
protein from positive clones revealed two bands, one having an apparent
molecular mass of 45 kDa (consistent with its identity as truncated
m144) and the other having an apparent molecular mass of 12 kDa,
corresponding to
2m. The calculated molecular mass of truncated m144
is 27 kDa, but the protein is glycosylated (4 potential N-linked
glycosylation sites [14, 39]) and would be expected to
migrate with a higher apparent molecular mass. Supernatants from
positive clones were passed over a BBM.1 immunoaffinity column, eluted,
then passed over a size exclusion column to separate free
2m from
2m-heavy chain heterodimers. An SDS-PAGE gel of the resulting
purified protein is shown in Fig. 2.
N-terminal sequencing of purified heterodimers confirmed the sequences
of the first 17 residues of the mature forms of h
2m (26)
and m144 (14, 39).
|
2m. Two antibodies were produced: 15C6,
which was raised against a gel slice of the m144 heavy chain, and 19G4,
which was raised against purified m144-h
2m heterodimers. CHO cells
were transfected with genes encoding truncated m144 and the b allele of
m
2m. Cells expressing m144-m
2m heterodimers could be identified
by immunoprecipitation with either the anti-m144 MAbs or a polyclonal
anti-
2m antiserum that recognizes m
2m, but not by
immunoprecipitation with the MAb S19.8 (48), which apparently does not react with m
2mb complexed with m144.
SDS-PAGE analysis of immunoprecipitated protein from cells expressing
m144 and m
2m also reveals two bands migrating at 45 and 12 kDa (data
not shown). m144-m
2m was purified from transfected cell supernatants
on an immunoaffinity column constructed with MAb 15C6 (Fig. 2).
N-terminal sequencing of purified protein established that the
heterodimer was composed of the mature forms of m144 and m
2m.
Sequences of hamster (16) and bovine (20)
2m
were not detected, indicating that m144 was not associating with
endogenous hamster
2m or exchanging with bovine
2m in the medium,
as can occur when mouse class I MHC proteins are expressed with m
2m
in CHO cells (13).
m144 does not bind endogenous peptides.
To determine if either
m144-h
2m or m144-m
2m binds peptides, purified proteins were
treated with acetic acid to dissociate potential peptide material
(24, 42, 51). Acid eluates were characterized by N-terminal
sequencing (see Table 1), HPLC, and mass spectrometry. Soluble versions
of other proteins expressed in CHO cells (the murine class I MHC
molecule H2-Kd and two other MHC class I homologs,
UL18 from HCMV and the rat neonatal Fc receptor, FcRn) were
subjected to the same treatment. Kd and UL18
had previously been shown to bind peptides and were used as positive
controls (10, 11, 37). FcRn does not bind peptides (7,
37) and was used as a negative control.
|
2m,
m144-m
2m, and FcRn did not show the presence of peptides (Table 1).
With the exception of cycle 1, which is typically subject to high
backgrounds, the total yield of the amino acids from each cycle of pool
sequencing of the acid eluates remained nearly constant, and this yield
was only slightly above background. In addition, most of the peaks in
the HPLC profile of the m144-h
2m acid eluate were also apparent in
eluates extracted from FcRn, and all were barely notable above the
background. When the few peaks that differed between the m144-h
m and
FcRn eluates were collected and characterized by mass spectrometry,
these peaks were found to contain low-molecular-weight material that
did not show proteinaceous characteristics (data not shown).
m144, but not UL18, is thermally stable in the absence
of peptides.
Class I MHC heavy chains show decreased stability in
the absence of bound peptide (13, 33, 50). To ascertain if
m144-h
2m or m144-m
2m is unstable due to the absence of bound
peptide, we monitored the heat-induced unfolding of these proteins by
recording the CD signal at 223 nm while increasing the sample
temperature from 25 to 75°C (Fig. 3A).
The results were compared with melting curves of partially empty and
peptide-filled forms of the class I MHC molecule H-2Kd
(Fig. 3B) (13). Two unfolding transitions are evident in the curve derived from m144-h
2m. The first, with a
Tm of 55°C, corresponds to the unfolding of
the m144 heavy chain, while the second, with a
Tm of 64°C, corresponds to the previously
observed Tm for h
2m (13) and
represents the independent unfolding of the light chain subsequent to
heavy-chain denaturation. m144-m
2m melts less cooperatively than
m144-h
2m and the derived Tm for the
heavy-chain unfolding (52°C) is slightly lower, indicating that m144
complexed with m
2m is somewhat less stable than m144 complexed with
h
2m. In addition, the downward-sloping transition for the melting of
2m is not apparent in the melting curve of m144-m
2m, perhaps
being obscured by the CD signal from the melted m144 heavy chain.
Similar results were obtained for the melting of Kd
complexed with m
2m (12). The melting behavior of both
forms of m144 is more similar to that of peptide-filled Kd
(Tm = 56°C for Kd-m
2m;
Tm = 57°C for Kd-h
2m) than to
that of empty Kd (Tm = 42°C for
Kd-m
2m; Tm = 45°C for
Kd-h
2m) (12, 13) (compare Fig. 3A and B),
suggesting that m144 is thermally stable in the absence of peptide.
|
CD spectral comparison of m144, UL18, FcRn, and class I
MHC.
The far-UV CD spectrum of m144 was compared with spectra of
other MHC homologs and a classical class I molecule (Fig.
4). Far-UV CD spectra were previously
used to characterize the secondary structures of class I MHC molecules
and FcRn (16, 18, 30). The available crystal structures of
FcRn and class I molecules (7, 47) can be used to verify the
conclusion derived from the CD spectra that the secondary-structure
arrangement of FcRn resembles, but is not identical to, class I MHC
structures. The spectra of all four molecules (m144-h
2m,
UL18, FcRn, and H-2Kd) show characteristics of
proteins that are composed primarily of
-structure with a minor
-helical conformation (25). However, the short-wavelength
portion of the m144 spectrum is red-shifted compared with the
H-2Kd and UL18 spectra and with part of the
FcRn spectrum. These results suggest that m144 has structural features
that distinguish it from UL18 and classical class I
molecules. Since all three types of proteins share the common feature
of
2m binding, it is likely that structural differences are
localized to regions distal from
2m, such as the top surface of the
1
2 platform (Fig. 1).
|
| |
DISCUSSION |
|---|
|
|
|---|
HCMV and MCMV both encode class I MHC homologs. Previous studies
indicated that UL18, the HCMV class I homolog, binds the class I light chain
2m (6) and associates with endogenous peptides (11). In this study, we expressed a soluble version of the MCMV class I homolog m144 and compared its biochemical characteristics to those of class I molecules and UL18. We
found that m144 expressed in CHO cells associates with both h
2m and m
2m, implying that m144 heterodimerizes with host-derived
2m in
virus-infected cells. However, unlike UL18 and class I
molecules, m144 does not bind endogenous peptides, since we do not
detect peptide material associated with either form of m144-
2m.
Other class I MHC homologs for which biochemical or structural studies do not reveal the presence of endogenous peptides include FcRn (7,
37), human Zn-
2-glycoprotein (44), and the
hemochromatosis gene product HFE (31a). In addition, human
MICA and mouse H-2T region-encoded molecules are stably expressed in
cells that lack a functional peptide transporter, suggesting that they
too do not bind conventional class I peptide ligands (9, 19, 23, 52).
A comparison of alignments of the m144 and UL18 sequences
with class I MHC sequences reveals that UL18 is more likely
than m144 to adopt a fold that includes an MHC-like peptide-binding groove (Fig. 1B). Peptides bind to class I MHC molecules in a groove
located between two
-helices that span an 8-stranded
-pleated sheet. Peptide termini are accommodated in pockets at each end of the
groove that are lined with conserved residues (reviewed in reference
47). The peptide N terminus binds in pocket A on the
left side of the groove (as depicted in Fig. 1B), in which four
conserved tyrosines make critical hydrogen bonds to main-chain atoms of
the peptide (residues 7, 59, 159, and 171; class I numbering) (Fig.
1A). These tyrosines are also found in the UL18 sequence, suggesting a similar mechanism for interaction with peptide N termini
(11). While the UL18 sequence shows some gaps
and insertions compared to class I sequences, these are primarily
confined to regions corresponding to the right side of the groove and
suggest that the UL18 structure may differ from MHC
structures in the region of the groove that interacts with peptide C
termini. Indeed, analysis of endogenous peptides associated with
UL18 revealed variability in the length of bound peptides
(11), whereas classical class I molecules show a strong
preference for binding octamer and nonamer peptides (reviewed in
reference 47). By contrast, only two of the four
pocket A tyrosines are conserved in the m144 sequence (Fig. 1A).
Furthermore, the
2 domain of m144 is significantly truncated
compared to those of class I and UL18 molecules, such that
strands 6 and 8 are much shorter, there is no predicted seventh
strand, and there is a large deletion within the predicted
2 domain
helix. These characteristics do not seem compatible with formation of a
functional peptide-binding groove, and they imply that this region of
m144 is structurally distinct from class I molecules and
UL18. Far-UV CD spectral differences support this prediction (Fig. 4).
Our finding that m144, unlike class I MHC molecules and
UL18, is thermally stable in the absence of bound peptide
is also consistent with a structural rearrangement in the counterpart of its peptide-binding region. CD melting curves of m144 complexed with
either h
2m or m
2m show that it is more stable than either an
empty class I molecule or partially empty UL18 (Fig. 3).
The melting curves of the empty forms of class I and UL18
were characterized by Tms between 42 and 45°C,
while the Tm of the m144-h
2m curve was
55°C, closer to the Tm for peptide-filled
Kd (56 to 57°C) (12, 13). m144 is slightly
less stable when complexed with m
2m (Tm = 52°C). This effect was also noted for the complex of m
2m with
Kd, compared with the complex of h
2m with Kd
(12), and more dramatically, for the complex of m
2m with
the nonclassical murine class I protein T10 (9). We were
able to analyze the effect of bound peptide on UL18
stability by taking advantage of the fact that soluble UL18
is only partially occupied with endogenous peptides when it is
expressed at high levels. Addition of a synthetic peptide corresponding
to the sequence of an endogenous peptide eluted from UL18
shifts the Tm to 66°C, thus formally
demonstrating that UL18 binds this peptide and suggesting a
general method for assaying peptide binding by UL18.
The different properties of UL18 and m144 revealed by this study do not, in and of themselves, undermine the contention that these molecules both function as surrogate class I proteins, capable of engaging NK cell inhibitory receptors and protecting cells that lack class I surface expression. Murine NK cell inhibitory receptors are homodimeric C-type lectin superfamily proteins, whereas the majority of characterized human inhibitory receptors are members of the immunoglobulin superfamily (reviewed in references 22 and 35). It is therefore conceivable that mouse NK inhibitory receptors would recognize features of mouse class I MHC molecules different from those recognized on human class I molecules by human inhibitory receptors. While there is no evidence yet of a direct interaction between a mouse inhibitory receptor and m144, recent results demonstrate that the presence of m144 interferes with NK cell-mediated clearance of virus-infected cells in vivo (14). The connection between UL18 and human NK cells is less straightforward. A recent study reported that UL18 expressed on a human class I-negative B-lymphoblastoid cell line inhibited NK cell lysis through interaction with the C-lectin-like inhibitory receptor CD94 (40). However, we and investigators at other laboratories have been unable to detect cell surface expression of UL18 when its gene was transfected into the same B-cell line (31b). Additional results indicate that the presence of UL18 on virus-infected fibroblasts slightly augments, rather than inhibits, NK cell-mediated lysis (31b). A probable host ligand for UL18 was recently identified as LIR-1, a new immunoglobulin superfamily member related to human NK inhibitory receptors (8). LIR-1 is expressed mainly on B cells and monocytes, but only on a subset of NK cells; thus, it is possible that the HCMV MHC homolog exerts its primary effects on host cells other than NK cells. Further studies will be necessary to resolve the roles of both m144 and UL18 in the interactions of their respective viruses with the immune systems of the infected hosts. However, currently available data suggest that the two homologs function differently, a hypothesis that is consistent with the biochemical and structural differences between m144 and UL18 observed in the present study.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by the Howard Hughes Medical Institute and by a grant from the Arthritis Foundation to P.J.B. T.L.C. is supported by a National Defense Science and Engineering Pre-Doctoral Fellowship.
We thank H. Farrell and N. Davis-Poynter for providing the m144 gene and for helpful discussions and critical reading of the manuscript. We also thank G. Hathaway and the Caltech Protein Peptide Micro Analytical Laboratory for peptide analysis, and members of the Bjorkman laboratory for critical reading of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Biology 156-29, Caltech, Pasadena, CA 91125. Phone: (626) 395-8350. Fax: (626) 792-3683. E-mail: bjorkman{at}cco.caltech.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bebbington, C. R., and C. C. G. Hentschel. 1987. The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells, p. 163-188. In D. M. Glover (ed.), DNA cloning: a practical approach. IRL Press, Oxford, United Kingdom. |
| 2. | Beck, S., and B. G. Barrell. 1988. Human cytomegalovirus encodes a glycoprotein homologous to MHC class I antigens. Nature 331:269-272[Medline]. |
| 3. | Bjorkman, P. J., and P. Parham. 1990. Structure, function and diversity of class I major histocompatibility complex molecules. Annu. Rev. Biochem. 90:253-288. |
| 4. | Bjorkman, P. J., M. A. Saper, B. Samraoui, W. S. Bennett, J. L. Strominger, and D. C. Wiley. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506-512[Medline]. |
| 5. | Britt, W. J., and C. A. Alford. 1996. Cytomegalovirus, p. 2493-2523. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields Virology. Lippincott-Raven, Philadelphia, Pa. |
| 6. |
Browne, H.,
G. Smith,
S. Beck, and T. Minson.
1990.
A complex between the MHC class I homologue encoded by human cytomegalovirus and 2 microglobulin.
Nature
347:770-772[Medline].
|
| 7. | Burmeister, W. P., L. N. Gastinel, N. E. Simister, M. L. Blum, and P. J. Bjorkman. 1994. Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptor. Nature 372:336-343[Medline]. |
| 8. | Cosman, D., N. Fanger, L. Borges, M. Kubin, W. Chin, L. Peterson, and M.-L. Hsu. 1997. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7:273-282[Medline]. |
| 9. |
Crowley, M. P.,
Z. Reich,
N. Mavaddat,
J. D. Altmann, and Y.-H. Chien.
1997.
The recognition of the nonclassical major histocompatibility complex (MHC) class I molecule, T10, by the ![]() T cell, G8.
J. Exp. Med.
185:1223-1230 |
| 10. |
Fahnestock, M. L.,
J. M. Dadgari,
M. McMillan, and P. J. Bjorkman.
1994.
Phosphatidyl inositol-linked forms of a murine class I MHC molecule expressed on CHO cells retain peptide binding capability and alloreactivity.
Int. Immunol.
6:307-314 |
| 11. | Fahnestock, M. L., J. L. Johnson, R. M. R. Feldman, J. M. Neveu, W. S. Lane, and P. J. Bjorkman. 1995. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity 3:583-590[Medline]. |
| 12. | Fahnestock, M. L., J. L. Johnson, R. M. R. Feldman, T. J. Tsomides, J. Mayer, L. O. Narhi, and P. J. Bjorkman. 1994. Effects of peptide length and composition on binding to an empty class I MHC heterodimer. Biochemistry 33:8149-8158[Medline]. |
| 13. |
Fahnestock, M. L.,
I. Tamir,
L. Narhi, and P. J. Bjorkman.
1992.
Thermal stability comparison of purified empty and peptide filled forms of a class I MHC molecule.
Science
258:1658-1662 |
| 14. | Farrell, H. E., H. Vally, D. M. Lynch, P. Fleming, G. R. Shellam, A. A. Scalzo, and N. J. Davis-Poynter. 1997. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 386:510-514[Medline]. |
| 15. | Gasser, D. L., K. A. Klein, E. Choi, and J. G. Seidman. 1985. A new beta-2 microglobulin allele in mice defined by DNA sequencing. Immunogenetics 22:413-416[Medline]. |
| 16. |
Gastinel, L. N.,
N. E. Simister, and P. J. Bjorkman.
1992.
Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules.
Proc. Natl. Acad. Sci. USA
89:638-642 |
| 17. |
Gates, F. T.,
J. E. Coligan, and T. J. Kindt.
1981.
Complete amino acid sequence of murine 2-microglobulin: structural evidence for strain-related polymorphism.
Proc. Natl. Acad. Sci. USA
78:554-558 |
| 18. |
Gorga, J. C.,
A. Dong,
M. C. Manning,
R. W. Woody,
W. S. Caughey, and J. L. Strominger.
1989.
Comparison of the secondary structures of human class I and class II major histocompatibility complex antigens by Fourier-transform infrared and circular dichroism spectroscopy.
Proc. Natl. Acad. Sci. USA
86:2321-2325 |
| 19. |
Groh, V.,
S. Bahram,
S. Bauer,
A. Herman,
M. Beauchamp, and T. Spies.
1996.
Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium.
Proc. Natl. Acad. Sci. USA
93:12445-12450 |
| 20. |
Groves, M. L., and R. Greenberg.
1982.
Complete amino acid sequence of bovine 2-microglobulin.
J. Biol. Chem.
257:2619-2626 |
| 21. | Harlow, E., and D. Lane. 1988. . Antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 22. | Höglund, P., J. Sundback, M. Y. Olsson-Anheim, M. Johansson, M. Salcedo, C. Öhlén, H. G. Ljunggren, C. L. Sentman, and K. Kärre. 1997. Host MHC class I control of NK-cell specificity in the mouse. Immunol. Rev. 155:11-28[Medline]. |
| 23. |
Holcombe, H. R.,
A. R. Castano,
H. Cheroutre,
M. Teitell,
J. K. Maher,
P. A. Peterson, and M. Kronenberg.
1995.
Nonclassical behavior of the thymus leukemia antigen peptide transporter-independent expression of a nonclassical class I molecule.
J. Exp. Med.
181:1433-1443 |
| 24. | Jardetzky, T. S., W. S. Lane, R. A. Robinson, D. R. Madden, and D. C. Wiley. 1991. Identification of self peptides bound to purified HLA-B27. Nature 353:325-330. |
| 25. | Johnson, C. W. 1990. Protein secondary structure and circular dichroism: a practical guide. Proteins Struct. Funct. Genet. 7:205-214. [Medline] |
| 26. | Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. . Sequences of proteins of immunological interest. U.S. Department of Health and Human Services, Bethesda, Md. |
| 27. | Kärre, K., H.-G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2 deficient lymphoma variants suggest alternative immune defense strategy. Nature 319:675-678[Medline]. |
| 28. | Kraulis, P. J. 1991. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:946-950. |
| 29. | Kunkel, T. A., J. D. Roberts, and R. A. Zakour. 1987. Rapid and efficient site directed mutagenesis without phenotypic selection. Methods Enzymol. 154:367-382[Medline]. |
| 30. |
Lancet, D.,
P. Parham, and J. L. Strominger.
1979.
Heavy chain of HLA-A and HLA-B antigens is conformationally labile: a possible role for 2-microglobulin.
Proc. Natl. Acad. Sci. USA
76:3844-3848 |
| 31. | Lanier, L. L., B. Corliss, and J. H. Phillips. 1997. Arousal and inhibition of human NK cells. Immunol. Rev. 155:145-154[Medline]. |
| 31a. | Lebrón, J. A., and P. J. Bjorkman. Unpublished data. |
| 31b. | Leong, C., T. L. Chapman, P. J. Bjorkman, E. Mocarski, and L. L. Lanier. Unpublished data. |
| 32. |
Lin, A. Y.,
B. Devaux,
A. Green,
C. Sagerström,
J. F. Elliott, and M. M. Davis.
1990.
Expression of T cell antigen receptor heterodimers in a lipid-linked form.
Science
249:677-679 |
| 33. | Ljunggren, H. G., N. J. Stam, C. Öhlén, J. J. Neefjes, P. Höglund, M. T. Heemels, J. Bastin, T. N. M. Schumacher, A. Townsend, K. Kärre, and H. L. Ploegh. 1990. Empty MHC class I molecules come out in the cold. Nature 346:476-480[Medline]. |
| 34. | Merritt, E. A., and M. E. P. Murphy. 1994. Raster3D version 2.0, a program for photorealistic molecular graphics. Acta Crystallogr. Sect. D 50:869-873. [Medline] |
| 35. | Moretta, A., R. Biassoni, C. Bottino, D. Pende, M. Vitale, A. Poggi, M. C. Mingari, and L. Moretta. 1997. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol. Rev. 155:105-117[Medline]. |
| 36. |
Parham, P.,
M. J. Androlewicz,
N. J. Holmes, and B. E. Rothenberg.
1983.
Arginine-45 is a major part of the determinant of human 2-microglobulin recognized by mouse monoclonal antibody BBM.1.
J. Biol. Chem.
258:6179-6186 |
| 37. | Raghavan, M., L. N. Gastinel, and P. J. Bjorkman. 1993. The class I MHC-related Fc receptor shows pH dependent stability differences correlating with immunoglobulin binding and release. Biochemistry 32:8654-8660[Medline]. |
| 38. | Rammensee, H.-G., K. Falk, and O. Rötzschke. 1993. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11:213-244[Medline]. |
| 39. | Rawlinson, W. D., H. E. Farrell, and B. G. Barrell. 1996. Analysis of the complete DNA sequence of murine cytomegalovirus. J. Virol. 70:8833-8849[Abstract]. |
| 40. | Reyburn, H. T., O. Mandelboim, M. Valez-Gomez, D. M. Davis, L. Pazmany, and J. L. Strominger. 1997. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 386:514-519[Medline]. |
| 41. |
Romero, P.,
G. Corradin,
I. F. Luescher, and J. L. Maryanski.
1991.
H-2Kd restricted antigenic peptides share a simple binding motif.
J. Exp. Med.
174:603-612 |
| 42. | Rötzschke, O., K. Falk, K. Deres, H. Schild, M. Norda, J. Metzger, G. Jung, and H.-G. Rammensee. 1990. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348:252-257[Medline]. |
| 43. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. . Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 44. |
Sánchez, L. M.,
C. López-Otín, and P. J. Bjorkman.
1997.
Characterization and crystallization of human Zn- 2-glycoprotein, a soluble class I MHC homolog.
Proc. Natl. Acad. Sci. USA
94:4626-4630 |
| 45. | Saper, M. A., P. J. Bjorkman, and D. C. Wiley. 1991. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J. Mol. Biol. 219:277-319[Medline]. |
| 46. | Schumacher, T. N. M., M. T. Heemels, J. J. Neefjes, W. M. Kast, C. J. M. Melief, and H. L. Ploegh. 1990. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 62:563-567[Medline]. |
| 47. | Stern, L. J., and D. C. Wiley. 1994. Antigenic peptide binding by class I and class II histocompatibility proteins. Structure 15:245-251. |
| 48. | Tada, N., S. Kimura, A. Hatzfeld, and U. Hammerling. 1980. Ly-m11: the H-3 region of mouse chromosome 2 controls a new surface alloantigen. Immunogenetics 11:441-449[Medline]. |
| 49. | Townsend, A., and H. Bodmer. 1989. Antigen recognition by class I-restricted T lymphocytes. Annu. Rev. Immunol. 7:601-624[Medline]. |
| 50. | Townsend, A., T. Elliott, V. Cerundolo, L. Foster, B. Barber, and A. Tse. 1990. Assembly of MHC class I molecules analyzed in vitro. Cell 62:285-295[Medline]. |
| 51. | Van Bleek, G. M., and S. G. Nathenson. 1990. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature 348:213-216[Medline]. |
| 52. | Weintraub, B. C., M. R. Jackson, and S. M. Hedrick. 1994. Gamma-delta T-cells can recognize nonclassical MHC in the absence of conventional antigenic peptides. J. Immunol. 153:3051-3058[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»